clinical trial · NCT07284667
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Major Depressive Disorder (MDD)Depressive Disorder, Treatment-ResistantACP-211Placebo
brief summary
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? * What adverse events do participants have when taking ACP-211?
started
Nov 14, 2025
primary completion
Aug 1, 2027
completion
Sep 1, 2027
last updated
Apr 17, 2026
official title
A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol